Table 1.
R0 (n = 20 853) | R1 (n = 3139) | No surgery (n = 4773) | Liver‐treated cohort (n = 1325) | P † | |
---|---|---|---|---|---|
Age (years) * | 72 (14–101) | 73 (19–106) | 74 (26–100) | 66 (25–87) | < 0·001 |
Sex | < 0·001 | ||||
M | 10 939 (52·5) | 1601 (51·0) | 2632 (55·1) | 812 (61·3) | |
F | 9914 (47·5) | 1538 (49·0) | 2141 (44·9) | 513 (38·7) | |
BMI (kg/m 2 ) | 0·015 | ||||
< 18·5 | 461 (2·2) | 124 (4·0) | 0 (0) | 16 (1·2) | |
18·5–25 | 8482 (40·7) | 1215 (38·7) | 13 (0·3) | 541 (40·8) | |
> 25 | 9908 (47·5) | 1060 (33·8) | 16 (0·3) | 682 (51·5) | |
Missing | 2002 (9·6) | 740 (23·6) | 4744 (99·4) | 86 (6·5) | |
ASA grade | < 0·001 | ||||
I–II | 14 403 (69·1) | 1716 (54·7) | 23 (0·5) | 1021 (77·1) | |
III–IV | 5680 (27·2) | 993 (31·6) | 10 (0·2) | 272 (20·5) | |
Missing | 770 (3·7) | 430 (13·7) | 4740 (99·3) | 32 (2·4) | |
Location of primary tumour | < 0·001 | ||||
Right colon | 6544 (31·4) | 930 (29·6) | 924 (19·4) | 268 (20·2) | |
Transverse colon | 1163 (5·6) | 194 (6·2) | 198 (4·1) | 44 (3·3) | |
Left colon | 6158 (29·5) | 915 (29·1) | 1581 (33·1) | 507 (38·3) | |
Rectum | 6419 (30·8) | 1021 (32·5) | 1964 (41·1) | 467 (35·2) | |
Multiple | 566 (2·7) | 71 (2·3) | 82 (1·7) | 39 (2·9) | |
Missing | 3 (0·01) | 8 (0·3) | 24 (0·5) | 0 (0) | |
pT status | < 0·001 | ||||
pT0 | 238 (1·1) | 30 (1·0) | n.a. | 15 (1·1) | |
pT1–2 | 5031 (24·1) | 201 (6·4) | 146 (11·0) | ||
pT3 | 12 273 (58·9) | 800 (25·5) | 915 (69·1) | ||
pT4 | 3241 (15·5) | 1211 (38·6) | 247 (18·6) | ||
pTX | 70 (0·3) | 897 (28·6) | 2 (0·2) | ||
pN status | < 0·001 | ||||
pN0 | 11 934 (57·2) | 683 (21·8) | n.a. | 465 (35·1) | |
pN1 | 5188 (24·9) | 548 (17·5) | 469 (35·4) | ||
pN2–3 | 3454 (16·6) | 791 (25·2) | 387 (29·2) | ||
pNX | 277 (1·3) | 1117 (35·6) | 4 (0·3) | ||
M status | < 0·001 | ||||
M0 | 18 513 (88·8) | 1768 (56·3) | 2078 (43·5) | 581 (43·8) | |
M1 (synchronous) | 2340 (11·2) | 1371 (43·7) | 2695 (56·5) | 744 (56·2) | |
Liver metastases only (synchronous) | 1229 (5·9) | 453 (14·4) | 1256 (26·3) | 611 (46·1) | |
Lung metastases only (synchronous) | 286 (1·4) | 87 (2·8) | 186 (3·9) | 8 (0·6) | |
Other metastases only (synchronous) | 380 (1·8) | 341 (10·9) | 142 (3·0) | 5 (0·4) | |
Multiple metastases (synchronous) | 445 (2·1) | 490 (15·6) | 1111 (23·3) | 120 (9·1) | |
Liver metastases only (metachronous) | 880 (4·2) | – | – | 436 (32·9) | |
Lung metastases only (metachronous) | 725 (3·5) | – | – | 92 (6·9) | |
Other metastases only (metachronous) | 546 (2·6) | – | – | 28 (2·1) | |
Multiple metastases (metachronous) | 1012 (4·8) | – | – | 188 (14·2) |
Values in parentheses are percentages unless indicated otherwise;
values are median (range). R0, all patients with colorectal adenocarcinoma registered in the Swedish Colorectal Cancer Register (SCRCR) (2009–2013) as having a radical resection; R1, all patients registered in the SCRCR (2009–2013) as not having a radical resection; no surgery, all patients registered in the SCRCR (2009–2013) with colorectal cancer not treated surgically; liver‐treated cohort, all patients registered in the SCRCR (2009–2013) as radically resected and registered in the Swedish Registry for Liver Surgery (SweLiv) (2009–2016) as treated for colorectal liver metastases at some time point. n.a., Not applicable.
R0 versus liver‐treated cohort (Pearson's χ2 test).